MARKET

ZNTL

ZNTL

Zentalis Pharmaceuticals, Inc.
NASDAQ
12.71
-0.17
-1.32%
After Hours: 12.71 0 0.00% 16:20 04/17 EDT
OPEN
13.03
PREV CLOSE
12.88
HIGH
13.31
LOW
12.58
VOLUME
810.14K
TURNOVER
0
52 WEEK HIGH
31.46
52 WEEK LOW
9.56
MARKET CAP
901.90M
P/E (TTM)
-2.8452
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ZNTL last week (0408-0412)?
Weekly Report · 2d ago
Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling
Zentalis Pharmaceuticals, Inc. Expects final results from phase 1b study of azenosertib for the treatment of patients with osteosarcoma in the 1st half of 2024. Zentalis is working on advancing its lead candidate in its pipeline. The drug could be approved for a gynecological indication in 2026.
Seeking Alpha · 5d ago
Zentalis Shares Fall After Chief Financial Officer Resigns
Zentalis Pharmaceuticals shares are down 8.4% to $13.49. Melissa Epperly resigned as chief financial officer, treasurer and accounting officer. The company didn't specify the reason for her departure. Zentalis is a clinical-stage biopharmaceutical company.
Dow Jones · 6d ago
Zentalis Pharmaceuticals says Melissa Epperly resigns as CFO
Healthcare Zentalis Pharmaceuticals says Melissa Epperly resigns as CFO. The company has appointed president, Cam Gallagher, as interim CFO to replace her. The firm is also conducting a search for a new finance chief. Zental is Pharmaceuticals, Inc. (ZNTL)
Seeking Alpha · 6d ago
Zentalis Pharmaceuticals Announces Executive Financial Transition
TipRanks · 6d ago
ZENTALIS PHARMACEUTICALS INC - ON APRIL 5, MELISSA EPPERLY RESIGNED AS CHIEF FINANCIAL OFFICER OF ZENTALIS PHARMACEUTICALS EFFECTIVE IMMEDIATELY
Reuters · 6d ago
ZENTALIS PHARMACEUTICALS INC - BOARD APPOINTED COMPANY'S PRESIDENT, CAM GALLAGHER, AS INTERIM CHIEF FINANCIAL OFFICER
Reuters · 6d ago
Zentalis Pharmaceuticals to Present at Upcoming Conferences
TipRanks · 04/09 20:43
More
About ZNTL
Zentalis Pharmaceuticals Inc is a United States-based company. The Company develops small molecule therapeutics with differentiated product profiles for a broad range of cancers. It is focused on pipeline of oncology candidates, which include azenosertib, a WEE1 inhibitor for advanced solid tumors, ZN-d5, a B-cell lymphoma 2 (BCL-2) inhibitor for hematologic malignancies and related disorders, and a heterobifunctional degrader of BCL-xL for solid and hematological malignancies.

Webull offers Zentalis Pharmaceuticals Inc stock information, including NASDAQ: ZNTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZNTL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZNTL stock methods without spending real money on the virtual paper trading platform.